Co-Diagnostics Inc. reported third quarter 2025 financial results with operating expenses of approximately $7.1 million, a decrease of 32.6% year-over-year. The company recorded an operating loss of $7.0 million, compared to $10.2 million in the same period last year, and a net loss of $5.9 million, or $0.16 per fully diluted share, versus a net loss of $9.7 million, or $0.32 per fully diluted share, in third quarter 2024. Adjusted EBITDA loss was $6.3 million. Cash, cash equivalents, and marketable securities totaled $11.4 million as of September 30, 2025. Business developments included the closing of a Registered Direct Offering with gross proceeds of $3.8 million, the signing of a definitive agreement for a joint venture in Saudi Arabia and 18 MENA markets, and the formation of a new artificial intelligence business unit. The company also developed a proprietary sample preparation instrument for its tuberculosis test and performed in-silico analysis confirming the effectiveness of its chikungunya virus primers.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-022283), on November 13, 2025, and is solely responsible for the information contained therein.
Comments